Despite lingering concerns about increased susceptibility to heart problems when taking Avandia, a Type 2 diabetes medication, the majority of a Federal Drug Administration advisory panel suggested that the drug have looser restrictions. It will now be up to FDA Commissioner Margaret Hamburg to make a decision.

Read the story.